CR6424A - Polimeros biodegradables encapsulados antagonistas del receptor serotonina y metodos para la preparacion de los mismos - Google Patents

Polimeros biodegradables encapsulados antagonistas del receptor serotonina y metodos para la preparacion de los mismos

Info

Publication number
CR6424A
CR6424A CR6424A CR6424A CR6424A CR 6424 A CR6424 A CR 6424A CR 6424 A CR6424 A CR 6424A CR 6424 A CR6424 A CR 6424A CR 6424 A CR6424 A CR 6424A
Authority
CR
Costa Rica
Prior art keywords
methods
serotonine
antagonists
receiver
preparation
Prior art date
Application number
CR6424A
Other languages
English (en)
Inventor
Rachel KOHN
Stephen Hanley
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of CR6424A publication Critical patent/CR6424A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)

Abstract

Una nueva clase de composición farmaceútica útil como fluído sostenible de composición médica, incluyendo métodos de fabricación y métodos de uso de estas composiciones, son descritas y reivindicadas. El método de fabricación de estas composiciones incluye los pasos de: a)mezcla seca de una molécula farmaceúticamente activa con polímero biodegradable. b)derretir extrayendo la mezcla para formar una solución sólida de la molécula activa en el polímero. c)pulverizar la solución sólida para formar micropartículas tales que puedan ser transformadas en soluciones inyectables.
CR6424A 1998-12-16 2001-07-16 Polimeros biodegradables encapsulados antagonistas del receptor serotonina y metodos para la preparacion de los mismos CR6424A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16

Publications (1)

Publication Number Publication Date
CR6424A true CR6424A (es) 2004-02-26

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6424A CR6424A (es) 1998-12-16 2001-07-16 Polimeros biodegradables encapsulados antagonistas del receptor serotonina y metodos para la preparacion de los mismos

Country Status (35)

Country Link
EP (1) EP1140026B1 (es)
JP (1) JP4759141B2 (es)
KR (1) KR100707710B1 (es)
CN (1) CN1195497C (es)
AP (1) AP1769A (es)
AR (1) AR021652A1 (es)
AT (1) ATE303795T1 (es)
AU (1) AU770673B2 (es)
BG (1) BG65500B1 (es)
BR (1) BR9916276A (es)
CA (1) CA2355077C (es)
CR (1) CR6424A (es)
CZ (1) CZ301947B6 (es)
DE (1) DE69927177T2 (es)
DK (1) DK1140026T3 (es)
EA (1) EA004502B1 (es)
EE (1) EE200100314A (es)
ES (1) ES2245128T3 (es)
HK (1) HK1041645B (es)
HR (1) HRP20010446A2 (es)
HU (1) HU226586B1 (es)
ID (1) ID28909A (es)
IL (2) IL143761A0 (es)
ME (2) MEP19408A (es)
NO (1) NO20012981L (es)
NZ (1) NZ511962A (es)
OA (1) OA11728A (es)
PL (1) PL196822B1 (es)
RS (1) RS50123B (es)
SK (1) SK285812B6 (es)
TR (1) TR200101759T2 (es)
TW (1) TWI221418B (es)
UA (1) UA73101C2 (es)
WO (1) WO2000035423A1 (es)
ZA (1) ZA200104899B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
WO2002075273A2 (en) * 2001-03-20 2002-09-26 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
US8501056B2 (en) * 2001-05-23 2013-08-06 Hexal Ag Homogenized product for implants and microparticles
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US8691277B2 (en) * 2004-09-21 2014-04-08 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
BRPI0913724B8 (pt) * 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
EP4084607A4 (en) * 2019-12-31 2023-06-21 Wanka Tanka Ltd. EXTENDED RELEASE PLASTIC FORMULATION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH679207A5 (es) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
WO1991017772A1 (en) * 1990-05-16 1991-11-28 Southern Research Institute Controlled release dopamine and its use to stimulate nerve fiber growth
CA2083698C (en) * 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法

Also Published As

Publication number Publication date
WO2000035423A9 (en) 2002-08-22
ME00066B (me) 2010-06-10
TR200101759T2 (tr) 2001-12-21
SK8282001A3 (en) 2001-11-06
DK1140026T3 (da) 2006-01-02
EA200100551A1 (ru) 2001-10-22
HUP0105048A3 (en) 2002-09-30
SK285812B6 (sk) 2007-08-02
ID28909A (id) 2001-07-12
WO2000035423A1 (en) 2000-06-22
AP2001002198A0 (en) 2001-09-30
EE200100314A (et) 2002-08-15
RS50123B (sr) 2009-03-25
KR20010082359A (ko) 2001-08-29
ATE303795T1 (de) 2005-09-15
CA2355077A1 (en) 2000-06-22
CZ301947B6 (cs) 2010-08-11
AU1742500A (en) 2000-07-03
AR021652A1 (es) 2002-07-31
NZ511962A (en) 2003-06-30
ES2245128T3 (es) 2005-12-16
CN1330536A (zh) 2002-01-09
BR9916276A (pt) 2001-09-04
HU226586B1 (en) 2009-04-28
IL143761A (en) 2006-08-01
AP1769A (en) 2007-08-22
TWI221418B (en) 2004-10-01
BG105591A (en) 2002-01-31
JP4759141B2 (ja) 2011-08-31
KR100707710B1 (ko) 2007-04-18
EA004502B1 (ru) 2004-04-29
DE69927177D1 (de) 2005-10-13
HK1041645A1 (en) 2002-07-19
OA11728A (en) 2005-02-01
PL196822B1 (pl) 2008-02-29
JP2002532408A (ja) 2002-10-02
EP1140026B1 (en) 2005-09-07
YU41401A (sh) 2003-12-31
HUP0105048A2 (hu) 2002-05-29
CN1195497C (zh) 2005-04-06
NO20012981D0 (no) 2001-06-15
MEP19408A (en) 2010-06-10
DE69927177T2 (de) 2006-06-08
IL143761A0 (en) 2002-04-21
HK1041645B (zh) 2005-07-29
CA2355077C (en) 2009-05-26
UA73101C2 (en) 2005-06-15
HRP20010446A2 (en) 2002-06-30
ZA200104899B (en) 2002-09-16
BG65500B1 (bg) 2008-10-31
AU770673B2 (en) 2004-02-26
CZ20012157A3 (cs) 2001-09-12
NO20012981L (no) 2001-07-27
PL348233A1 (en) 2002-05-20
EP1140026A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
CR6424A (es) Polimeros biodegradables encapsulados antagonistas del receptor serotonina y metodos para la preparacion de los mismos
AR008927A1 (es) Una composicion farmaceutica que comprende una sustancia medicinalmente activa insoluble en agua con propiedades mejoradas de disolucion, absorcion, etc., y el procedimiento para prepararla
NZ599594A (en) Fast dissolving solid dosage form
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
EP2106787A3 (en) Biodegradable block copolymeric compositions for drug delivery
PE20091778A1 (es) Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden
DE69906269D1 (de) Wässriges verfahren zur herstellung fester paroxetin-dispersionen
KR890701082A (ko) 신속히 용해되는 의약 용량 유니트 및 이의 제조방법
ITTO20000963A1 (it) Microparticella a rilascio prolungato e metodo per la sua preparazione.
PE20060003A1 (es) Formulacion farmaceutica polimerica para moldear por inyeccion
AR042193A1 (es) Composiciones farmaceuticas que tienen un vehiculo modificado
ATE349202T1 (de) Formulierung auf heparin-, glycosaminoglykan- oder heparinoidbasis und verwendung der formulierung sowie der formulierungsgrundlage
DK1067911T3 (da) Hydrogelsammensætninger, der kan anvendes til opretholdt frigivelse af makromolekyler, samt fremgansmåder tilfremstilling deraf
AR082566A1 (es) Formulaciones liquidas de st-246 y metodos relacionados, proceso
JP2005509052A5 (es)
NZ629769A (en) Topical gels containing alpha connexin c-terminal (act) peptides
ES2099075T3 (es) Conjugados de antraciclina con un nuevo engarce y procedimientos para su produccion.
AR039166A1 (es) Composiciones de venlafaxina base
ATE386516T1 (de) Anthelmintische zusammensetzungen
CN105733220B (zh) 含沼渣的生物降解塑料及其制备方法
CN105079818B (zh) 用乙酰胺和环糊精制备氟苯尼考可溶性粉
ES2727335T3 (es) Método para producir biocelulosa seca
AR051758A1 (es) Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida
AR044831A1 (es) Forma de administracion inyectable de la flupirtina
ES2059471T3 (es) Un procedimiento para preparar un derivado de rodamina.

Legal Events

Date Code Title Description
FC90 Application suspended